Literature DB >> 28087282

Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats.

Mohammad Zandi1, Arash Dehghan2, Amirhossein Mohammadi-Mofrad3, Payam Amini4, Farshid Vahdatinia5.   

Abstract

OBJECTIVE: Dentoalveolar procedures in patients receiving bisphosphonates and other antiresorptive agents are associated with an increased risk of medication-related osteonecrosis of the jaw (MRONJ). The aim of present study was to evaluate the effects of perioperative teriparatide (TPD) therapy in prevention of MRONJ. SUBJECTS AND METHODS: Two protocols of TPD therapy were studied. For protocol A, 25 TPD-treated (AT) and 25 control (AC) rats received 5 weekly injection of 0.06 mg/kg zoledronate. At the end of week 5, extraction of bilateral mandibular first molars was performed for all rats, and 4-week TPD (20 μg/kg/day) and saline therapy was started for AT and AC rats, respectively. For protocol B, 25 TPD-treated (BT) and 25 control (BC) rats received 5 weekly injection of 0.06 mg/kg zoledronate. One week later, 4-week TPD and saline therapy was started for BT and BC rats, respectively. Both groups underwent tooth extraction at the end of week 7 of the experiment. All rats were sacrificed 8 weeks after tooth extraction and assessed clinically for bone exposure/fistula, and histologically for density of osteocytes in newly formed bone and empty osteocyte lacunae in alveolar bone.
RESULTS: Incidence of bone exposure/fistula and mean numbers of osteocytes and empty lacunae per 25 mm2 (at 400× magnification) were 20%, 15.36, and 2.63 in AT group; 78%, 5.78, and 6.81 in AC group; 14%, 16.94, and 2.08 in BT group; and 78%, 7.54, and 5.95 in BC group; respectively. The differences between AT and AC and between BT and BC were statistically significant (P < 0.001). However, no statistically significant difference between AT and BT and between AC and BC was found.
CONCLUSION: Four weeks of TPD therapy, beginning at the same day or 2 weeks before tooth extraction, had a potential role in prevention of ONJ.
Copyright © 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bisphosphonate; Jaw; Osteonecrosis; Osteoporosis; Prevention; Teriparatide

Mesh:

Substances:

Year:  2016        PMID: 28087282     DOI: 10.1016/j.jcms.2016.12.010

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  5 in total

1.  A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.

Authors:  Y Ohbayashi; A Iwasaki; F Nakai; T Mashiba; M Miyake
Journal:  Osteoporos Int       Date:  2019-11-25       Impact factor: 4.507

2.  The effect of melatonin on prevention of bisphosphonate-related osteonecrosis of the jaw: an animal study in rats.

Authors:  Afshin Yadegari; Atousa Aminzadeh; Sam Seyyedkhamesi; Maedeh Aminian
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2020-08-31

Review 3.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

4.  Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study.

Authors:  Rodolfo Mauceri; Vera Panzarella; Laura Maniscalco; Alberto Bedogni; Maria Ester Licata; Antonino Albanese; Francesca Toia; Enzo Maria Giuseppe Cumbo; Giuseppina Mazzola; Olga Di Fede; Giuseppina Campisi
Journal:  Biomed Res Int       Date:  2018-08-19       Impact factor: 3.411

Review 5.  Applications of Teriparatide for Alveolar Bone Regeneration: A Systematic Review.

Authors:  Rupali Agnihotri; Sumit Gaur
Journal:  J Int Soc Prev Community Dent       Date:  2021-11-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.